Disease relevance of Pseudomyxoma Peritonei

• A patient with pseudomyxoma peritonei secondary to a mucin-secreting adenocarcinoma demonstrated striking, diffuse uptake of 99mTc-MDP throughout the abdomen [1].
• Cytoreductive surgery and perioperative intraperitoneal chemotherapy with mitomycin C and 5-fluorouracil may be considered as an accepted treatment for appendiceal malignancy with mucinous peritoneal carcinomatosis or for pseudomyxoma peritonei [2].
• Acidic glycosaminoglycans of abdominal mucin in a case of pseudomyxoma peritonei caused by appendiceal cancer [3].
• High expression of RELP (Reg IV) in neoplastic goblet cells of appendiceal mucinous cystadenoma and pseudomyxoma peritonei [4].
• AIMS AND BACKGROUND: Pseudomyxoma peritonei is a rare disease characterized by a complete redistribution of mucin within the peritoneal cavity [5].

High impact information on Pseudomyxoma Peritonei

• Unusual abdominal tumors, case 1. Pseudomyxoma peritonei: response to capecitabine [6].
• Extracellular mucin accumulates dramatically in pseudomyxoma peritonei because the number of MUC2-secreting cells dramatically increase and because this MUC2 has no place to drain [7].
• Primary epithelial cell cultures obtained from pseudomyxoma peritonei express MUC2 whose levels can be epigenetically regulated [7].
• These cells also express MUC5AC but the latter mucin is not specific for pseudomyxoma peritonei [7].
• Our studies revealed that pseudomyxoma peritonei is a disease of MUC2-expressing goblet cells [7].

Chemical compound and disease context of Pseudomyxoma Peritonei

• Successful treatment of pseudomyxoma peritonei of ovarian origin with cis-platinum, doxorubicin, and cyclophosphamide [8].
• This is the first case of pseudomyxoma peritonei secondary to an ovarian primary possibly cured by systemic cis-platinum, doxorubicin, and cyclophosphamide [8].
• To test the mucolytic effect of 5% and 10% dextrose-water solutions and to determine what could be a true mucolytic agent, in vitro and in vivo studies were undertaken in two proven pseudomyxoma peritonei cases [9].
• Response of pseudomyxoma peritonei to gemcitabine [10].
• Accumulation of technetium-99m MDP in pseudomyxoma peritonei [11].

Biological context of Pseudomyxoma Peritonei

• Our observation revealed an abundant mucin production with pools of mucin similar to those of pseudomyxoma peritonei and an inflammatory infiltrate with prominent lipid phagocytosis [12].

Anatomical context of Pseudomyxoma Peritonei

• The evidence suggests that if mucinous or gelatinous ascitic fluid is received in the laboratory and is shown to contain a dual cell population of round cells of mesothelial origin and spindle-shaped cells of fibroblastic origin together with lakes of fibrillar mucin, a cytologic diagnosis of pseudomyxoma peritonei can be made with confidence [13].
• At laparotomy, pseudomyxoma peritonei was discovered, together with a midline abdominal mass adherent to the anterior abdominal wall originating from the fundus of the bladder [14].
• A case of pseudomyxoma peritonei, a rare mucin-secreting tumour in the peritoneum, in a 30-year-old male and presenting as sub-acute large bowel obstruction, is reported here with review of the literature [15].

Gene context of Pseudomyxoma Peritonei

• MUC2 is a molecular marker for pseudomyxoma peritonei [16].
• Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19.9 measurements in patients with pseudomyxoma peritonei treated with cytoreduction and hyperthermic intraperitoneal chemotherapy [17].
• Synchronous mucinous tumors of the appendix and the ovary associated with pseudomyxoma peritonei. A clinicopathologic study of six cases with comparative analysis of c-Ki-ras mutations [18].
• Three of four ovarian tumors complicated by pseudomyxoma peritonei were negative for cytokeratin 7, indicating appendiceal origin [19].
• Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome [20].

Analytical, diagnostic and therapeutic context of Pseudomyxoma Peritonei

• Both immunocytochemical as well as in situ hybridization studies with ancillary digital image analysis reveal that MUC2 expression in cases of pseudomyxoma peritonei is independent of the degrees of malignant transformation that are present and, in fact, reflects the constitutive levels of expression observed in normal goblet cells of the appendix [7].
• BACKGROUND: Pseudomyxoma peritonei, a tumor which spreads chiefly along peritoneal surfaces, has recently been treated by resection followed by intraperitoneal infusion of 5-fluorouracil (5-FU) [21].

References